Borrelia burgdorferi escape mutants that survive in the presence of antiserum to the OspA vaccine are killed when complement is also present

Infection and Immunity

Volumn 66, Issue 6, 1998, Pages 2540-2546

  Solé, Mónica ^a,d   Bantar, Carlos ^a,e   Indest, Karl ^a   Gu, Yan ^a   Ramamoorthy, Ramesh ^a   Coughlin, Richard ^b   Philipp, Mario T ^a,c  

^a TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^b Aquila Biopharmaceuticals Inc   (United States)

^c TRPRC   (United States)

^d UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^e CEMIC   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; BACTERIAL VACCINE; COMPLEMENT;

ARTICLE; BACTERIUM MUTANT; BORRELIA BURGDORFERI; CARBOXY TERMINAL SEQUENCE; MOLECULAR CLONING; NONHUMAN; OPERON; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RHESUS MONKEY; SPIROCHETE;

BORRELIA BURGDORFERI;

EID: 0031812735     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.66.6.2540-2546.1998     Document Type: Article

References (37)

1. Aydintug, M. K., Y. Gu, and M. T. Philipp. 1994. Borrelia burgdorferi antigens that are targeted by antibody-dependent, complement-mediated killing in the rhesus monkey. Infect. Immun. 62:4929-4937.
2. Barthold, S. W. 1996. Lyme borreliosis in the laboratory mouse. J. Spirochetal Tick-Borne Dis. 3:22-44.
3. Barthold, S. W., E. Fikrig, L. K. Bockenstedt, and D. H. Persing. 1995. Circumvention of outer surface protein A immunity by host-adapted Borrelia burgdorferi. Infect. Immun. 63:2255-2261.
4. Cinco, M. 1992. Selection of a Borrelia burgdorferi antigenic variant by cultivation in the presence of increasing amounts of homologous immune serum. FEMS Microbiol. Lett. 92:15-18.
5. Coleman, J. L., R. C. Rogers, and J. L. Benach. 1992. Selection of an escape variant of Borrelia burgdorferi by use of bactericidal monoclonal antibodies to OspB. Infect. Immun. 60:3098-3104.
6. Comstock, L. E., E. Fikrig, R. J. Shoberg, R. A. Flavell, and D. D. Thomas. 1993. A monoclonal antibody to OspA inhibits association of Borrelia burgdorferi with human endothelial cells. Infect. Immun. 61:423-431.
7. Coughlin R. T., D. Fish, T. N. Mather, J. Ma, C. Pavia, and P. Bulger. 1995. Protection of dogs from Lyme disease with a vaccine containing outer surface protein (Osp) A, OspB, and the saponin adjuvant QS21. J. Infect. Dis. 171:1049-1052.
8. de Silva, A. M., S. R. Telford, 3rd, L. R. Brunet, S. W. Barthold, and E. Fikrig. 1996. Borrelia burgdorferi OspA is an arthropod-specific transmission-blocking Lyme disease vaccine. J. Exp. Med. 83:271-275.
9. de Silva, A. M., and E. Fikrig. 1995. Growth and migration of Borrelia burgdorferi in Ixodes ticks during blood feeding. Am. J. Trop. Med. Hyg. 53:397-404.
10. Fikrig, E., H. Tao, F. S. Kantor, S. W. Barthold, and R. A. Flavell. 1993. Evasion of protective immunity by Borrelia burgdorferi by truncation of outer surface protein B. Proc. Natl Acad. Sci. USA 90:4092-4096.
11. Fikrig, E., S. R. Telford III, S. W. Barthold, F. S. Kantor, A. Spielman, and R. A. Flavell. 1992. Elimination of Borrelia burgdorferi from vector ticks feeding on OspA-immunized mice. Proc. Natl. Acad. Sci. USA 89:5418-5421.
12. Fikrig, E., H. Tao, S. W. Barthold, and R. A. Flavell. 1995. Selection of variant Borrelia burgdorferi isolates from mice immunized with outer surface protein A or B. Infect. Immun. 63:1658-1662.
13. Gern, L., O. Rais, C. Capiau, P. Hauser, Y. Lobet, E. Simoen, P. Voet, and J. Pêtre. 1994. Immunization of mice by recombinant OspA preparations and protection against Borrelia burgdorferi infection induced by Ixodes ricinus tick bites. Immunol. Lett. 39:249-258.
14. Golde, W. T., T. R. Burkot, J. Piesman, M. C. Dolan, C. Capiau, P. Hauser, G. Dequesne, and Y. Lobet. 1995. The Lyme disease vaccine candidate outer surface protein A (OspA) in a formulation compatible with human use protects mice against natural tick transmission with Borrelia burgdorferi. Vaccine 13:435-441.
15. Kalish, R. A., A. C. Steere, and J. M. Leong. 1995. Early and late antibody responses to full-length and truncated constructs of outer surface protein A of Borrelia burgdorferi in Lyme disease. Infect. Immun. 63:2228-2235.
16. Keller, D., F. T. Koster, D. H. Marks, P. Hosbach, L. F. Erdile, and J. P. Mays. 1994. Safety and immunogenicity of a recombinant outer surface protein A Lyme vaccine. JAMA 271:1764-1768.
17. Kochi, S. M., R. C. Johnson, and A. P. Dalmasso. 1991. Complementmediated killing of the Lyme disease spirochete Borrelia burgdorferi. Role of antibody in formation of an effective membrane attack complex. J. Immunol. 146:3964-3970.
18. Kochi, S. M., R. C. Johnson, and A. P. Dalmasso. 1993. Facilitation of complement-dependent killing of the Lyme disease spirochete, Borrelia burgdorferi, by specific immunoglobulin G Fab antibody fragments. Infect. Immun. 61:2532-2536.
19. Kochi, S. M., and R. C. Johnson. 1988. Role of immunoglobulin G in killing of Borrelia burgdorferi by the classical complement pathway. Infect. Immun. 56:314-321.
20. Ma, J. P., R. T. Coughlin, P. Bulger, P. M. Franchi, and C. Gingrich-Baker. 1995. Molecular analysis of neutralizing epitopes on outer surface proteins A and B of Borrelia burgdorferi. Infect, Immun. 63:2221-2227.
21. Ma, J. P., M. Hine, E. R. Clough, D. Fish, R. T. Coughlin, G. A. Beltz, and M. G. Shew. 1996. Safety, efficacy, and immunogenicity of a recombinant Osp subunit canine Lyme disease vaccine. Vaccine 14:1366-1374.
22. Mather, T. N., M. T. Yeh, J. M. C. Ribeiro, A. Scorpio, D. R. Nelson, and R. T. Coughlin. 1996. Ixodes saliva: vector competence for Borrelia burgdorferi and potential vaccine strategies, abstr. A029. In Abstracts of the VII International Congress on Lyme Borreliosis. San Francisco, Calif.
23. Nowlings, J., and M. Philipp. Unpublished data.
24. Philipp, M. T., and B. J. B. Johnson. 1994. Animal models of Lyme disease: pathogenesis and immunoprophylaxis. Trends Microbiol. 2:431-437.
25. Philipp, M. T., Y. Lobet, R. P. Bohm, Jr., M. D. Conway, V. A. Dennis, P. Desmons, Y. Gu, P. Hauser, R. C. Lowrie, Jr., and E. D. Roberts. 1996. Safety and immunogenicity of recombinant outer surface protein A (OspA) vaccine formulations in the rhesus monkey. J. Spirochetal Tick-Borne Dis. 3:67-79.
26. Philipp, M. T., Y. Lobet, R. P. Bohm, Jr., E. D. Roberts, V. A. Dennis, Y. Gu, R. C. Lowrie, Jr., P. Desmons, P. H. Duray, J. England, P. Hauser, J. Piesman, and K. Xu. 1997. Efficacy of recombinant outer surface protein A (OspA) vaccine formulations in the rhesus monkey. Vaccine 15:1872-1887.
27. Rosa, P. A., T. Schwan, and D. Hogan. 1992. Recombination between genes encoding major outer surface proteins A and B of Borrelia burgdorferi. Mol. Microbiol. 6:3031-3040.
28. Sadziene, A., and A. G. Barbour. 1995. Growth inhibition of Borrelia burgdorferi sensu lato by antibodies. A contribution to understanding the pathogenesis and improving diagnosis of Lyme borreliosis. Wien. Med. Wochenschr. 145:162-165.
29. Sadziene, A., P. A. Rosa, P. A. Thompson, D. M. Hogan, and A. G. Barbour. 1992. Antibody-resistant mutants of Borrelia burgdorferi: in vitro selection and characterization. J. Exp. Med. 176:799-809.
30. Sanger, F. S., S. Nicklen, and A. R. Coulson. 1977. DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. USA 74:5463-5467.
31. Schoen, R. T., F. Meurice, C. M. Brunet, S, Cretella, D. S. Krause, J. E. Craft, and E. Fikrig. 1995. Safety and immunogenicity of an outer surface protein A vaccine in subjects with previous Lyme disease. J. Infect. Dis. 172:1324-1329.
32. Schutzer, S. E., P. K. Coyle, and M. Brunner. 1992. Identification of specific Borrelia burgdorferi components in circulating antigen-antibody complexes, p. 135-148. In S. E. Schutzer (ed.), Lyme disease: molecular and immunologic approaches. Current communications in cell and molecular biology. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
33. Schwan, T. G., M. E. Schrumpf, R. H. Karstens, J. R. Clover, J. Wong, M. Daugherty, M. Struthers, and P. A. Rosa. 1993. Distribution and molecular analysis of Lyme disease spirochetes, Borrelia burgdorferi, isolated from ticks throughout California. J. Clin. Microbiol. 31:3096-3108.
34. Shoberg, R. J., M. Jonsson, A. Sadziene, S. Bergstrom, and D. D. Thomas. 1994. Identification of a highly cross-reactive outer surface protein B epitope among diverse geographic isolates of Borrelia spp. causing Lyme disease. J. Clin. Microbiol. 32:489-500.
35. Telford, S. R., III, F. S. Kantor, Y. Lobet, S. W. Barthold, A. Spielman, R. A. Flavell, and E. Fikrig. 1995. Efficacy of human Lyme disease vaccine formulations in a mouse model. J. Infect. Dis. 171:1368-1370.
36. van Hoecke C., M. Comberbach, D. de Grave, P. Desmons, D. Fu, P. Hauser, E. Lebacq, Y. Lobet, and P. Voet. 1996. Evaluation of the safety, reactogenicity and immunogenicity of three recombinant outer surface protein (OspA) Lyme vaccines in healthy adults. Vaccine 14:1620-1626.
37. Wormser, G. P. 1996. Lyme disease vaccine. Infection 24:203-207.